Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double-blinded study

Gynecologic Oncology

Volumn 107, Issue 2, 2007, Pages 219-222

  Mathiesen, Ole ^a   Buus, Sanne K ^b   Cramers, Marie ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Randomised double blinded placebo controlled; Topical imiquimod; Vulvar intraepithelial neoplasia

Indexed keywords

FLUOROURACIL; IMIQUIMOD; PLACEBO;

ADULT; AGED; APPLICATION SITE BURNING; APPLICATION SITE REACTION; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG MECHANISM; FEMALE; HUMAN; PATIENT COMPLIANCE; PRECANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUMOR BIOPSY; VULVA CANCER;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; ADULT; AGED; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA IN SITU; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; PAIN; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VULVAR NEOPLASMS;

EID: 35348917434     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.06.003     Document Type: Article

References (23)

1. Jones R.W., and Rowan DM. Vulvar intraepithelial neoplasia III: a clinical study of outcome of 113 cases with relation to the later development of invasive vulvar carcinoma. Obstet. Gynecol. 84 (1994) 741-745
2. van Seters M., van Beurden M., and de Craen A.J.M. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol. Oncol. 97 (2005) 645-651
3. Buscema J., Nagashfar Z., Sawada E., Daniel R., Woodruff D., and Shah K. The predominance of human papillomavirus type 16 in vulvar neoplasia. Obstet. Gynecol. 71 (1988) 601-606
4. Srodon M., Stoler M.H., Baber G.B., and Kurman R.J. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am. J. Surg. Pathol. 30 (2006) 1513-1518
5. Hillemanns P., and Wang X. Integration of HPV-16 and HPV-18 in vulvar intraepithelial neoplasia. Gynecol. Oncol. 100 (2006) 276-282
6. Kaufman R.H. Intraepithelial neoplasia of the vulva. Gynecol. Oncol. 56 (1995) 8-21
7. Hillemanns P., Wang X., Staehle S., Michels W., and Dannecker C. Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO(2) laser vaporization, photodynamic therapy, excision and vulvectomy. Gyn. Oncol. 100 (2006) 271-275
8. Edwards L., Ferenczy A., Eron L., Baker D., Owens M.L., Fox T.L., et al. KA and the HPV-study group. Arch. Dermatol. 134 (1998) 25-30
9. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3 (2002) 196-200
10. Miller R., Gerster J.F., Owens M.L., Slade H.B., and Tomai MA. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int. J. Immunopharmacol. 21 (1999) 1-14
11. Stanley M.A. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dermatol. 2 7 (2002) 571-577
12. Gaspari A.A., and Sauder D.N. Immunotherapy of basal cell carcinoma: evolving approaches. Dermatol. Surg. 29 (2003) 1027-1034
13. Jayne C.J., and Kaufmann R.H. Treatment of vulvar intraepthelial neoplasia 2/3 with imiquimod. J. Reprod. Med. 47 (2002) 395-398
14. Todd R.W., Etherington I.J., and Luesley D.M. The effects of 5% imiquimod cream on high-grade vulval intraepithelial neoplasia. Gyn. Oncol. 85 (2002) 67-70
15. van Seters M., Fons G., and van Beurden M. Imiquimod in the treatment of multifocal vulvar intra epithelial neoplasia. J. Reprod. Med. 47 (2002) 701-705
16. Davies G., Wentworth J., and Richard J. Self-administrated topical imiquimod treatment of vulvar intraepithelial neoplasia. J. Reprod. Med. 45 (2000) 619-623
17. Patel G.K., Goodwin R., Chawia M., Laidler P., Price P.E., Finlay A.Y., et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomised, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 54 (2006) 1025-1032
18. Le T., Hicks W., Menard C., Hopkins L., and Fung M.F.K. Preliminary results of 5% imiquimod cream in the primary treatment of vulva intraepithelial neoplasia grade 2/3. Am. J. Obstet. Gynecol. 194 (2006) 377-380
19. Beutner K.R., and Geisse J.K. Imiquimod-an immune response modifier for the treatment of genital warts. Today's Ther. Trends 15 (1997) 165-178
20. Edwards L., Ferency A., Eron L., Baker D., Owens M.L., Fox T.L., et al. Schmitt KA and the HPV study group. Arch. Dermatol. 134 (1998) 25-30
21. Hillemanns P., Wang X., Staehle S., Michels W., and Dannecker C. Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO(2) laser vaporization, photodynamic therapy, excision and vulvectomy. Gynecol. Oncol. 100 (2006) 271-275
22. Dodge J.A., Eltabbakh G.H., Mount S.L., Walker R.P., and Morgan A. Clinical features and risk of recurrence among patients with vaginal intraepithelial neoplasia. Gynecol. Oncol. 83 2 (2001) 363-369
23. Graham B.D., Jetmore A.B., Foote J.E., and Arnold LK. Topical 5-fluorouracil in the management of extensive anal Bowen's disease: a preferred approach. Dis. Colon Rectum 48 (2005) 444-450